Business Wire

LabVantage Solutions and The Netherlands Forensic Institute (NFI) Partner to Advance Digital Transformation in Forensic Science

Share

—New Collaboration Enhances NFI’s IT Infrastructure with Advanced LIMS to Streamline Workflows, Improve Data Integrity, and Optimize Forensic Operations—

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, and The Netherlands Forensic Institute (NFI) today jointly announced a partnership to digitalize forensic laboratory workflows as part of NFI’s IT renewal initiative. A key aspect of this collaboration is the implementation of LabVantage Solutions’ Laboratory Information Management System (LIMS), which is designed to streamline NFI’s forensic operations by replacing fragmented processes and incorporating advanced capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204274659/en/

null

(Graphic: Business Wire)

NFI’s IT renewal initiative aims to modernize its infrastructure by replacing outdated manual systems with streamlined, automated workflows. Currently, the workflows involve multiple manual registrations across different systems, which can lead to time-consuming tasks and potential inconsistencies. The integration of LabVantage LIMS will unify data entry and enhance traceability, ensuring that data is efficiently recorded and utilized. It will also improve overall clarity and operational efficiency across forensic investigations, saving valuable time for all involved.

Peter Blom, Chief Information Officer of NFI, expressed his enthusiasm for the project: “This partnership marks a significant milestone in our journey to innovate and improve our forensic services. By integrating a sophisticated LIMS, we are setting a new standard in forensic science.”

“We are proud to work alongside NFI in their mission to enhance forensic operations,” said Michel Gerlicher, President, LabVantage International. “This collaboration will bring about a new era of efficiency and reliability in their laboratory workflows.”

The project includes contributions from Protinus, which served as the IT broker, and Capgemini, which is developing the sovereign cloud infrastructure to host the LIMS. The new system will integrate seamlessly into NFI’s operations, ensuring compliance with stringent security standards while enabling forensic experts to work faster and more confidently. By leveraging a secure, sovereign cloud infrastructure, the partnership will meet the highest standards of data protection and regulatory compliance, including BIO (Baseline Information Security for Government) and BBN (Baseline Information Security for Enterprises) requirements.

Alan Marcus, Chief Growth Officer at LabVantage Solutions, emphasized the broader implications of this alliance: “We are excited to see the real-life impact our investments in industry-specific solutions bring to our clients. With Software-as-a-Service (SaaS) becoming the de facto delivery standard, we expect vertical solutions to prove increasingly impactful, allowing clients to benefit from the latest innovations without being held back by past adaptations required by industry-agnostic software. NFI’s validation that our forensics solutions are fit for purpose is encouraging, and we are humbled to contribute to the fact-finding mission of NFI’s world-leading forensic laboratories.”

LabVantage Solutions, in joint effort with Protinus and Capgemini, will ensure the new system is secure and fully compliant with all required standards. By implementing LabVantage LIMS, NFI will streamline processes, enhance data accuracy, and improve data management, reinforcing its commitment to innovation and reliability. This partnership strengthens NFI’s role as a leader in delivering reliable forensic services to organizations around the world, while further establishing LabVantage Solutions’ prominence in the enterprise laboratory software solutions industry.

To learn more about LabVantage Solutions’ end-to-end informatics solutions for the complete forensic life cycle, please visit labvantage.com or contact us here.

About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. Its highly configurable, 100% browser-based platform consists of LIMS, ELN, LES, SDMS, and advanced analytics, supporting seamless deployment into any environment. Serving over 1,500 customers across life sciences, pharmaceuticals, biobanking, food & beverage, forensics, and more, LabVantage Solutions empowers innovation, helps improve product quality, and ensures compliance with industry regulations. Headquartered in Somerset, NJ, with offices worldwide, LabVantage Solutions has driven laboratory digital transformation for over 40 years. For more information, visit labvantage.com.

About The Netherlands Forensic Institute (NFI):
The Netherlands Forensic Institute is dedicated to providing high-quality forensic services to support justice, peace, and security. The NFI has achieved this position by constantly improving its products and services. Science and innovation at the NFI are strongly driven by experiences from forensic practice. Through this innovative approach and commitment to excellence, the NFI serves both national and international clients, offering a wide range of forensic products and services. For more information, visit https://www.forensischinstituut.nl/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204274659/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release

The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye